Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS).

Full DD Report for SNSS

You must become a subscriber to view this report.


Recent News from (NASDAQ: SNSS)

Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chroni...
Source: GlobeNewswire
Date: December, 02 2018 12:00
Sunesis Pharmaceuticals, Inc. (SNSS) CEO Dayton Misfeldt on Q3 2018 Results - Earnings Call Transcript
Sunesis Pharmaceuticals, Inc. (SNSS) Q3 2018 Earnings Conference Call November 05, 2018, 16:30 ET Executives William Quinn - SVP, Finance & Corporate Development and CFO Dayton Misfeldt - Interim CEO & Director Judith Fox - Chief Scientific Officer Analysts Marc Fra...
Source: SeekingAlpha
Date: November, 05 2018 18:56
Sunesis Pharmaceuticals beats by $0.01
Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q3 GAAP EPS of -$0.18 beats by $0.01. More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 05 2018 16:08
Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter ended September 30, 2018. Loss from operations for the three and nin...
Source: GlobeNewswire
Date: November, 05 2018 16:05
Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two poster presentations and an oral presentation at the 60 th American Society of Hematology (ASH) Annual Meeting being held December 1-4, 2018 in San Diego, Califor...
Source: GlobeNewswire
Date: November, 01 2018 09:17
Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Monday, November 5 th , 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarter ...
Source: GlobeNewswire
Date: October, 29 2018 07:00
Et Tu, Bruton?
Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales ...
Source: SeekingAlpha
Date: August, 30 2018 11:15
Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Wells Fargo Securities 2018 Hea...
Source: GlobeNewswire
Date: August, 30 2018 07:00
Sunesis Pharmaceuticals' (SNSS) Management on Q2 2018 Results - Earnings Call Transcript
Sunesis Pharmaceuticals, Inc. (SNSS) Q2 2018 Earnings Conference Call August 7, 2018 4:30 PM ET Executives Willie Quinn – Chief Financial Officer and Senior Vice President-Corporate Development Dayton Misfeldt – Interim Chief Executive Officer Judy Fox – Chie...
Source: SeekingAlpha
Date: August, 07 2018 19:15
Sunesis Pharmaceuticals beats by $0.04
Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q2 EPS of -$0.20 beats by $0.04 . More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 16:07

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.400.39510.41990.380437407,764
2018-12-100.470.41960.470.40548,279
2018-12-070.420.4590.480.40251,040,997
2018-12-060.490.42310.490.4002526,790
2018-12-050.530.490.550.4311,028,005

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1128,017130,89421.4043Cover
2018-12-1083,436116,60471.5550Short
2018-12-07116,255302,24938.4633Short
2018-12-0648,04996,61249.7340Short
2018-12-0480,041194,46341.1600Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SNSS.


About Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)

Logo for Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)

Not available

 

Contact Information

 

 

Current Management

  • Daniel N. Swisher, Jr. / CEO, President
  • Eric Bjerkholt / CFO, EVP, Corp. Dev.
  • Adam R. Craig / Consultant

Current Share Structure

  • Market Cap: $95,146,500 - 05/18/2018
  • Issue and Outstanding: 34,348,917 - 03/01/2018

 


Recent Filings from (NASDAQ: SNSS)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: July, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 25 2018

 

 


Daily Technical Chart for (NASDAQ: SNSS)

Daily Technical Chart for (NASDAQ: SNSS)


Stay tuned for daily updates and more on (NASDAQ: SNSS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SNSS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SNSS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SNSS and does not buy, sell, or trade any shares of SNSS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/